Banerjee S, Michalarea V, Ang JE, Ingles Garces A, et al. A phase I trial of CT900, a novel alpha-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer. Clin Cancer Res 2022 Aug 19. pii: 708154. doi: 10.1158/1078-0432.CCR-22-1268.
PMID: 35984704